Mirum Pharmaceuticals
Foster City
About Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $765.5M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2025)
- Ticker: nasdaq:MIRM
- Website: mirumpharma.com
- Phone: 650-667-4085
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/mirum-pharmaceuticals-94319 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.